Zika virus tests can now get to market faster, with fewer hurdles

US health regulators are reclassifying Zika virus tests. This moves them from the highest regulatory category to a lower one. This means manufacturers can bring these tests to market more quickly, with less upfront review.

For years, new medical devices faced a long, expensive approval process, even for well-understood technologies. This change means that a specific type of diagnostic test can now follow a faster path to market. It signals a shift towards streamlining approvals for devices where the risks are well-understood and can be managed with specific safety controls.